» Articles » PMID: 9359023

Classification, Diagnosis and Treatment of Vascular Dementia

Overview
Journal Drugs Aging
Specialties Geriatrics
Pharmacology
Date 1997 Nov 14
PMID 9359023
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Vascular dementia (VAD) is considered to be the second most common cause of dementia in Europe and the US. In Asia and many developing countries, it is more common than dementia of the Alzheimer's type (DAT). VAD is the most preventable form of dementia associated with later life. The pathogenesis of VAD is multifactorial, and it represents a heterogeneous, not a homogeneous, clinical entity. Classification of VAD by pathogenesis is important for its prevention and treatment. Control of the risk factors for VAD reduces its incidence and stabilises or improves cognitive performance following stroke. Proper diagnostic evaluation of VAD requires: (i) a well defined quantitative assessment of the cognitive deficits present; (ii) assessment of risk factors for stroke; (iii) identification of cerebral vascular lesions by history, neurological examination and neuroimaging; (iv) exclusion of other causes of dementia; (v) establishment of a positive diagnosis of possible, probable or definite VAD versus DAT or mixed VAD/DAT; and (vi) identification of the temporal relationship between cognitive deficits and cerebral vascular lesions. VAD can be subdivided into 8 major types, as follows: (i) multi-infarct dementia secondary to large cerebral emboli [type 1]; (ii) strategically placed infarctions causing dementia [type 2]; (iii) multiple subcortical lacunar lesions secondary to atherosclerosis or degenerative arteriolar changes [type 3]; (iv) Binswanger's disease (arteriosclerotic subcortical leukoencephalopathy) [type 4]; (v) mixtures of types 1, 2 and 3 [type 5]; (vi) haemorrhagic lesions causing dementia [type 6]; (vii) subcortical dementia secondary to hereditary factors (type 7); and (viii) mixtures of DAT and VAD (type 8). Treatment is dictated by the pathogenetic subtype of VAD that is present.

Citing Articles

Exploring the Link between Anticoagulation, Cognitive Impairment and Dementia in Atrial Fibrillation: A Systematic Review.

Agarwal A, Mostafa M, Ahmad M, Soliman E J Clin Med. 2024; 13(8).

PMID: 38673694 PMC: 11051417. DOI: 10.3390/jcm13082418.


Hexahydrocurcumin attenuated demyelination and improved cognitive impairment in chronic cerebral hypoperfusion rats.

Jearjaroen P, Thangwong P, Tocharus C, Chaichompoo W, Suksamrarn A, Tocharus J Inflammopharmacology. 2023; 32(2):1531-1544.

PMID: 38153537 DOI: 10.1007/s10787-023-01406-7.


The effects of CNS atrophy and ICVD on tests of executive function and functional status are mediated by intelligence.

Royall D, Palmer R Cereb Circ Cogn Behav. 2023; 5:100184.

PMID: 37811522 PMC: 10550593. DOI: 10.1016/j.cccb.2023.100184.


TGF-β Signaling: A Therapeutic Target to Reinstate Regenerative Plasticity in Vascular Dementia?.

Kandasamy M, Anusuyadevi M, Aigner K, Unger M, Kniewallner K, Bessa de Sousa D Aging Dis. 2020; 11(4):828-850.

PMID: 32765949 PMC: 7390515. DOI: 10.14336/AD.2020.0222.


Non-vitamin K Antagonist Oral Anticoagulants and Cognitive Impairment in Atrial Fibrillation: Insights From the Meta-Analysis of Over 90,000 Patients of Randomized Controlled Trials and Real-World Studies.

Zhang C, Gu Z, Shen L, Pan M, Yan Y, Pu J Front Aging Neurosci. 2018; 10:258.

PMID: 30333742 PMC: 6176145. DOI: 10.3389/fnagi.2018.00258.


References
1.
Wallin A, Blennow K . The clinical diagnosis of vascular dementia. Dementia. 1994; 5(3-4):181-4. DOI: 10.1159/000106719. View

2.
Wade J, Mirsen T, Hachinski V, Fisman M, Lau C, Merskey H . The clinical diagnosis of Alzheimer's disease. Arch Neurol. 1987; 44(1):24-9. DOI: 10.1001/archneur.1987.00520130016010. View

3.
Masawa N, Yoshida Y, Yamada T, JOSHITA T, Sato S, Mihara B . Morphometry of structural preservation of tunica media in aged and hypertensive human intracerebral arteries. Stroke. 1994; 25(1):122-7. DOI: 10.1161/01.str.25.1.122. View

4.
Shaw T, Mortel K, Meyer J, Rogers R, Hardenberg J, Cutaia M . Cerebral blood flow changes in benign aging and cerebrovascular disease. Neurology. 1984; 34(7):855-62. DOI: 10.1212/wnl.34.7.855. View

5.
Tierney M, Fisher R, Lewis A, Zorzitto M, SNOW W, Reid D . The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases. Neurology. 1988; 38(3):359-64. DOI: 10.1212/wnl.38.3.359. View